Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection

HIV Medicine

Volumn 15, Issue 2, 2014, Pages 108-115

  Martel Laferriere V ^a   Brinkley, S ^b   Bichoupan, K ^a   Posner, S ^a   Stivala, A ^a   Perumalswami, P ^a   Schiano, T D ^a   Sulkowski, M ^b   Dieterich, D T ^a   Branch, A D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coinfection; Hepatitis C virus; HIV; Side effects; Telaprevir

Indexed keywords

HEMOGLOBIN; PEGINTERFERON; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

ADULT; AFRICAN AMERICAN; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; DRUG ERUPTION; DRUG WITHDRAWAL; FEMALE; HEMOGLOBIN DETERMINATION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENTION TO TREAT ANALYSIS; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; PRIORITY JOURNAL; RECTUM DISEASE; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT RESPONSE;

COINFECTION; HEPATITIS C VIRUS; HIV; SIDE EFFECTS; TELAPREVIR;

ANEMIA; ANTIVIRAL AGENTS; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; SERINE PROTEINASE INHIBITORS; VIRAL LOAD;

EID: 84891835213     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12086     Document Type: Article

References (28)

1. Rockstroh JK, Mocroft A, Soriano V etal. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192: 992-1002.
2. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
3. Brau N, Salvatore M, Rios-Bedoya CF etal. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44: 47-55.
4. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271-278.
5. Laguno M, Murillas J, Blanco JL etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18: F27-F36.
6. Carrat F, Bani-Sadr F, Pol S etal. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 2839-2848.
7. Chung RT, Andersen J, Volberding P etal. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-459.
8. Torriani FJ, Rodriguez-Torres M, Rockstroh JK etal. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-450.
9. Nunez M, Miralles C, Berdun MA etal. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007; 23: 972-982.
10. Ghany M, Nelson D, Strader D, Thomas D, Seeff L. An update on treatment of genotype 1 chronic hepatitis c virus infection: practice guideline by the american association for the study of liver diseases. Hepatology 2011; 54: 1433-1444.
11. Jacobson IM, McHutchison JG, Dusheiko G etal. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
12. Sherman KE, Flamm SL, Afdhal NH etal. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-1024.
13. Zeuzem S, Andreone P, Pol S etal. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
14. Sulkowski MS, Sherman KE, Dieterich DT etal. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159: 86-96.
15. Vallet-Pichard A, Mallet V, Nalpas B etal. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-36.
16. Table for Grading the Severity of Adult and Pediatric Adverse Events. Version 1.0 - December 2004 (Clarification dated August 2009). Available at http://rsc.tech-res.com/safetyandpharmacovigilance/gradingtables.aspx (accessed 7 February 2013).
17. Mira JA, Garcia-Rey S, Rivero A etal. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Clin Infect Dis 2012; 55: 1719-1726.
18. Zeremski M, Dimova RB, Makeyeva J etal. IL28B polymorphism, pretreatment CXCL10 and HCV RNA levels predict treatment response in racially diverse HIV/HCV co-infected and HCV mono-infected patients. J Acquir Immune Defic Syndr 2012; 63: 9-16.
19. Cotte L, Braun J, Lascoux-Combe C etal. High Early Virological Response with Telaprevir-Pegylated-Interferon-Ribavirin in Treatment-experienced Hepatitis C Virus Genotype 1/HIV Co-infected Patients: ANRS HC26 TelapreVIH Study. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, March 2013.
20. Bichoupan K, Giannattasio E, Martel-Laferriere V etal. Side effects and adverse outcomes of telaprevir-based triple therapy in HCV-positive patients with and without advanced fibrosis: real life experience. Hepatology 2012; S1: 1010A.
21. TM (telaprevir) Film Coated Tablets, for oral use. Available at http://pi.vrtx.com/files/uspi_telaprevir.pdf (accessed 29 August 2013).
22. Heeswijk R, Garg V, Boogaerts G etal. The Pharmacokinetic Interaction Between Telaprevir & Raltegravir in Healthy Volunteers. 51st ICAAC. Chicago, IL, September 2011 [Abstract A1-1738a].
23. Heeswijk R, Vandevoorde A, Boogaerts G etal. Pharmacokinetic Interactions between ARV Agents and the Investigational HCV Protease Inhibitor TVR in Healthy Volunteers. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2011 [Abstract 119].
24. Kakuda T, Leopold L, Nijs S etal. Telaprevir and Etravirine or Rilpivirine. 13th HIV PK Workshop. Barcelona, Spain, April 2012 [Abstract O-18].
25. Garg V, Chandorkar G, Yang Y etal. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers. Br J Clin Pharmacol 2013; 75: 431-439.
26. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed 29 August 2013).
27. Reiss P, Battegay M, Clumeck N etal. European AIDS Cilnical Society Guidelines. Version 2011; 6: 1-60.
28. Victrelis (boceprevir) Capsules for oral use: Full prescribing information. Available at www.accessdata.fda.gov/drugsatfda_docs/label/2013/202258s003lbl.pdf (accessed 29 August 2013).